Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuPharma ( (GB:IMM) ) just unveiled an update.
ImmuPharma has launched a retail equity offer via the Winterflood Retail Access Platform to raise up to £1.5 million by issuing 25 million new ordinary shares at 6 pence each, matching the price of a separate £7.5 million institutional subscription announced the same day. The combined fundraising, which is subject to shareholder approval and AIM admission in early April, aims to give U.K. retail investors parity of access while expanding the company’s capital base, though it will dilute existing holdings and remains contingent on the success of the larger subscription.
The WRAP retail offer, open only to eligible U.K. investors through participating intermediaries, carries a minimum subscription of £100 and is expected to close on 20 March with results due around 23 March. By using regulatory exemptions to avoid publishing a full prospectus, ImmuPharma is opting for a quicker, lower‑cost capital raise, but investors are explicitly warned that the shares are high‑risk, may result in total loss of capital, and are not being marketed outside the United Kingdom.
The most recent analyst rating on (GB:IMM) stock is a Sell with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.
Spark’s Take on IMM Stock
According to Spark, TipRanks’ AI Analyst, IMM is a Neutral.
The score is weighed down primarily by very weak financial performance (near-zero revenue, persistent losses, ongoing cash burn, and negative equity). Technicals are mixed but modestly supportive versus the 200-day average, while valuation remains challenged due to losses and the absence of dividend yield.
To see Spark’s full report on IMM stock, click here.
More about ImmuPharma
ImmuPharma PLC is a specialist drug discovery and development company listed on London’s AIM market. The group focuses on developing novel therapeutic candidates, positioning itself within the biotech and pharmaceutical R&D segment of the healthcare industry, and targets investors seeking exposure to early‑stage and clinical‑stage drug innovation.
Average Trading Volume: 3,202,727
Technical Sentiment Signal: Buy
Current Market Cap: £34.94M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.